Growth Momentum Compumedics reports record FY26 revenue of AUD 60.3 million with EBITDA of AUD 5.4 million and a year-over-year revenue increase, signaling expanding market appetite for its diagnostic technologies and potential upsell opportunities to existing customers.

Geographic Expansion Appointment of a United States Chief Commercial Officer and ongoing US commercial rollout indicate a strategic push into North America, presenting opportunities to pursue US-based hospitals, clinics, and distributors with the company’s MEG, SOMS, and Nexus platforms.

Product Mix Pressures Gross margin declined to 51% due to product mix, tariffs, and input cost pressures, highlighting opportunities to position higher-margin solutions, negotiate bundled offerings, or introduce cost-competitive service contracts to improve profitability.

SaaS Upsell SaaS segment grew around 70% driven by Somfit and Nexus 360, suggesting strong demand for cloud-enabled diagnostics and data analytics; sales teams should target clinics and labs for subscription-based upgrades and cross-sell to adjacent modules.

Leadership and Governance Board changes with the resignation of a non-executive director and ongoing development phase imply a focusing on strategic growth and governance; leverage this period to engage executive stakeholders for major procurement or long-term partnership discussions.